Icotrokinra
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Editor's Highlights-June 2026.
Journal: International journal of dermatology
Published: April 21, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study.
Journal: Journal of the American Academy of Dermatology
Published: February 24, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled Trial.
Journal: Journal of the American Academy of Dermatology
Published: February 20, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 13, 2026
Safety and Efficacy of the Oral IL-23 Receptor Antagonist Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of cutaneous medicine and surgery
Published: February 12, 2026
Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.
Journal: Skin therapy letter
Published: January 20, 2026
Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis.
Journal: Clinical and experimental dermatology
Published: January 16, 2026
Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Journal: International journal of dermatology
Published: January 11, 2026
A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Journal: Inflammopharmacology
Published: January 08, 2026
Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Journal: Frontiers in immunology
Published: December 15, 2025
Oral icotrokinra for plaque psoriasis in adults and adolescents.
Journal: Annals of medicine and surgery (2012)
Published: November 09, 2025
Last Updated: 06/30/2026